Management of adjuvant settings for Stage ...
Type de document :
Compte-rendu et recension critique d'ouvrage
DOI :
PMID :
Titre :
Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database
Auteur(s) :
Dalle, Stéphane [Auteur]
Hospices Civils de Lyon [HCL]
Centre de Recherche en Cancérologie de Lyon [UNICANCER/CRCL]
Varey, Emilie [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Centre d’Investigation Clinique de Nantes [CIC Nantes]
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA]
Nguyen, Jean-Michel [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA]
Dupuy, Alain [Auteur]
CRLCC Eugène Marquis [CRLCC]
Montaudie, Henri [Auteur]
Hôpital l'Archet
Lesage, Candice [Auteur]
Hôpital Saint Eloi [CHU Montpellier]
Mortier, Laurent [Auteur]
Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 [OncoThAI]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Leccia, Marie-Thérèse [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Skowron, François [Auteur]
Celerier, Philippe [Auteur]
Meyer, Nicolas [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Dutriaux, Caroline [Auteur]
CHU Bordeaux
Dalac-Rat, Sophie [Auteur]
CHU Dijon
Khammari, Amir [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Centre d’Investigation Clinique de Nantes [CIC Nantes]
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA]
Lebbe, Céleste [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Dréno, Brigitte [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Centre d’Investigation Clinique de Nantes [CIC Nantes]
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA]
Hospices Civils de Lyon [HCL]
Centre de Recherche en Cancérologie de Lyon [UNICANCER/CRCL]
Varey, Emilie [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Centre d’Investigation Clinique de Nantes [CIC Nantes]
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA]
Nguyen, Jean-Michel [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA]
Dupuy, Alain [Auteur]
CRLCC Eugène Marquis [CRLCC]
Montaudie, Henri [Auteur]
Hôpital l'Archet
Lesage, Candice [Auteur]
Hôpital Saint Eloi [CHU Montpellier]
Mortier, Laurent [Auteur]
Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 [OncoThAI]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Leccia, Marie-Thérèse [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Skowron, François [Auteur]
Celerier, Philippe [Auteur]
Meyer, Nicolas [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Dutriaux, Caroline [Auteur]
CHU Bordeaux
Dalac-Rat, Sophie [Auteur]
CHU Dijon
Khammari, Amir [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Centre d’Investigation Clinique de Nantes [CIC Nantes]
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA]
Lebbe, Céleste [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Dréno, Brigitte [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Centre d’Investigation Clinique de Nantes [CIC Nantes]
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA]
Titre de la revue :
EUROPEAN JOURNAL OF DERMATOLOGY
Pagination :
389-396
Éditeur :
John Libbey Eurotext
Date de publication :
2020-08
ISSN :
1167-1122
Mot(s)-clé(s) en anglais :
BRAF
adjuvant treatment
immunotherapy
melanoma
sentinel lymph node
targeted treatment
adjuvant treatment
immunotherapy
melanoma
sentinel lymph node
targeted treatment
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background: Targeted therapies such as BRAF and MEK inhibitors and immunotherapies have been made available to treat melanoma.Objectives: To provide an overview of the management of the French Stage III melanoma population ...
Lire la suite >Background: Targeted therapies such as BRAF and MEK inhibitors and immunotherapies have been made available to treat melanoma.Objectives: To provide an overview of the management of the French Stage III melanoma population after complete lymph node resection prior to new adjuvant therapies.Materials and methods: A subgroup data analysis.Results: Data from 1,835 patients were analysed (15.58% Stage IIIA, 39.24% Stage IIIB, 43.92% Stage IIIC and 1.25% Stage IIID). Superficial spreading melanoma was the most frequent (70.98% in Stage IIIA for whom mutation analysis was performed; BRAF mutation was identified in up to 62% Stage IIIA patients). Sentinel lymph node biopsy was performed in 88.46% of Stage IIIA patients, 42.36% of Stage IIIB, 53.97% of Stage IIIC and 34.78% of Stage IIID. Up to 80% of Stage IIIA patients had no adjuvant treatment follow-up. Ulceration (p = 0.004; RR: 2.98; 95% CI: 1.4-6.3) and age at diagnosis (p = 0.0002; RR: 1.04; 95% CI: 1.02-1.06) were significant predictive factors for survival. Adjuvant interferon-α was administered in up to 13.04% of Stage IIID patients.Conclusion: Only a small number of Stage III melanoma patients were treated with interferon-α in adjuvant settings. New adjuvant therapies are currently having an effect on clinical practice in France, increasing survival and decreasing cost.Lire moins >
Lire la suite >Background: Targeted therapies such as BRAF and MEK inhibitors and immunotherapies have been made available to treat melanoma.Objectives: To provide an overview of the management of the French Stage III melanoma population after complete lymph node resection prior to new adjuvant therapies.Materials and methods: A subgroup data analysis.Results: Data from 1,835 patients were analysed (15.58% Stage IIIA, 39.24% Stage IIIB, 43.92% Stage IIIC and 1.25% Stage IIID). Superficial spreading melanoma was the most frequent (70.98% in Stage IIIA for whom mutation analysis was performed; BRAF mutation was identified in up to 62% Stage IIIA patients). Sentinel lymph node biopsy was performed in 88.46% of Stage IIIA patients, 42.36% of Stage IIIB, 53.97% of Stage IIIC and 34.78% of Stage IIID. Up to 80% of Stage IIIA patients had no adjuvant treatment follow-up. Ulceration (p = 0.004; RR: 2.98; 95% CI: 1.4-6.3) and age at diagnosis (p = 0.0002; RR: 1.04; 95% CI: 1.02-1.06) were significant predictive factors for survival. Adjuvant interferon-α was administered in up to 13.04% of Stage IIID patients.Conclusion: Only a small number of Stage III melanoma patients were treated with interferon-α in adjuvant settings. New adjuvant therapies are currently having an effect on clinical practice in France, increasing survival and decreasing cost.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Source :